Cargando…

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series

Objective: National centralized drug procurement organized by the Chinese government currently represents the largest group purchasing organization worldwide, to establish a reasonable price formation mechanism. This study aimed to evaluate the effects of centralized procurement policy on drug price...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Hongfei, Yang, Ying, Geng, Xin, Mao, Zongfu, Mao, Zhenhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335887/ https://www.ncbi.nlm.nih.gov/pubmed/35910351 http://dx.doi.org/10.3389/fphar.2022.944540

Ejemplares similares

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
por: Wang, Ni, et al.
Publicado: (2021)

The change of drug utilization in China’s public healthcare institutions under the “4 + 7” centralized drug procurement policy: Evidence from a natural experiment in China
por: Lu, Jiancheng, et al.
Publicado: (2022)

The Effects of a New Public Medicine Procurement Policy on Medicine Price in Shaanxi Province, Western China: An Interrupted Time Series Analysis
por: Hu, Shuchen, et al.
Publicado: (2019)

The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
por: Yang, Ying, et al.
Publicado: (2021)

Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls
por: Chen, Yilin, et al.
Publicado: (2021)

Impact of the Low-Price Medicine Policy on Medicine Supply in China: An Interrupted Time-Series Analysis
por: Zhao, Mingyue, et al.
Publicado: (2021)

Antibiotic Use in China’s Public Healthcare Institutions During the COVID-19 Pandemic: An Analysis of Nationwide Procurement Data, 2018–2020
por: Yang, Ying, et al.
Publicado: (2022)

The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis
por: Yang, Ying, et al.
Publicado: (2021)

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
por: Chen, Lei, et al.
Publicado: (2020)

A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China
por: Wen, Xiaotong, et al.
Publicado: (2023)

PHARMACEUTICAL PRICING IN EMERGING MARKETS: EFFECTS OF INCOME, COMPETITION, AND PROCUREMENT
por: Danzon, Patricia M, et al.
Publicado: (2015)

Does China’s centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model
por: Gu, Yang, et al.
Publicado: (2023)

The impact of key monitoring policy on the usage of policy-related drugs in Hubei Province, China
por: Wen, Xiaotong, et al.
Publicado: (2023)

Healthcare professionals’ knowledge, attitude and practice towards National Centralized Drug Procurement policy in central China: A cross-sectional study
por: Huang, Anqi, et al.
Publicado: (2022)

The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis
por: Wang, Xiao, et al.
Publicado: (2023)

Collective pharmaceutical procurement in China may have unintended consequences in supply and pricing
por: Jiang, Shan, et al.
Publicado: (2020)

The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis
por: Wen, Xiaotong, et al.
Publicado: (2021)

Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China
por: Li, Zhuoxian, et al.
Publicado: (2021)

Pharmaceutical procurement among public sector procurers in CARICOM
por: Preston, Charles, et al.
Publicado: (2021)

The impacts of the “4+7” pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study
por: Wen, Xiaotong, et al.
Publicado: (2022)

Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement
por: Zhang, Wen, et al.
Publicado: (2023)

The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis
por: Rong, Xuejing, et al.
Publicado: (2020)

Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus
por: Yuan, Jing, et al.
Publicado: (2022)

Impact of ‘4+7’ volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China
por: Wang, Jing, et al.
Publicado: (2022)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

Factors influencing global antiretroviral procurement prices
por: Wirtz, Veronika J, et al.
Publicado: (2009)

Editorial: Pharmaceutical policy, impact and health outcomes
por: Kwon, Hye-Young, et al.
Publicado: (2023)

The Impact of a National Stewardship Policy on the Usage Patterns of Key Monitoring Drugs in a Tertiary Teaching Hospital: An Interrupted Time Series Analysis
por: Li, Haiyan, et al.
Publicado: (2022)

Proofs for PLOS ONE Paper : Does Pharmaceutical Pricing Transparency Matter? Examining Brazil’s Public Procurement System
por: Kohler, Jillian Clare, et al.
Publicado: (2015)

Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China
por: Yuan, Jing, et al.
Publicado: (2021)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Impact of China’s National Centralized Drug Procurement Policy on pharmaceutical enterprises’ financial performance: a quasi-natural experimental study
por: Sun, Zhixuan, et al.
Publicado: (2023)

CERN Procurement Strategy and Policy
Publicado: (2011)

Pharmaceutical Pricing Policy in Greece: Toward a Different Path
por: Souliotis, Kyriakos, et al.
Publicado: (2016)

An overview of procurement, pricing, and uptake of COVID-19 vaccines in Pakistan
por: Siddiqui, Adeel, et al.
Publicado: (2021)

Evaluation of the effect of managing oxycodone/acetaminophen as a psychotropic medicine: An interrupted time-series study
por: Xiang, Cheng, et al.
Publicado: (2023)

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications
por: Salek, Sam M., et al.
Publicado: (2019)

Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure
por: Vogler, Sabine, et al.
Publicado: (2021)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9bsc5cfi6tthg07vtkefugk550